ClinicalTrials.gg
RecruitingNCT04753996Updated Feb 17, 2026

Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients

An observational study in Primary Sclerosing Cholangitis, PSC and Cholangiocarcinoma, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Mayo Clinic · Observational

How we know

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Cholangitis, Sclerosing by Mayo Clinic — 4 open to participants now, 4 under way, none of them phase 3. Cholangitis, Sclerosing · Mayo Clinic.

Started
2021
the only one that year
Observational
5 of 13
2 open now
Registered
11th of 13
by date

Among the 13 studies in Cholangitis, Sclerosing by Mayo Clinic, this one is the only one that started in 2021, is one of 5 observational ones, and was the 11th registered.

Cholangitis, Sclerosing

152 studies on the registry are indexed under Cholangitis, Sclerosing; 42 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

4 of the 13 studies in Cholangitis, Sclerosing by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Cholangitis, Sclerosing by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.

Read the detailed description

The study will ask participants to provide bile and/or bile duct cytology brushings at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal). The bile and brushings will be used to generate and perpetuate bile-derived organoids using an established matrigel-based protocol. These organoids will then be used in downstream experiments to better understand disease-specific alterations to biological pathways informative of disease pathogenesis

03

Conditions studied

  • Primary Sclerosing Cholangitis
  • PSC
  • Cholangiocarcinoma
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects with Primary Sclerosing Cholangitis (PSC) and controls without PSC will be able to participate in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

PSC

  • Patients diagnosed with PSC between the age of 18 and 85.
  • The diagnosis of PSC will be based on standard PSC criteria including clinical and biochemical evidence of chronic cholestasis of at least six months duration, positive cholangiographic findings and compatible liver if available.
  • Women with PSC of and pregnant women will be offered enrollment because there is no risk to an unborn child in this investigation. Patients with PSC and Cholangiocarcinoma will be included.

Controls

  • Controls without history of PSC or evidence of other chronic liver disease of either gender that will participate in this study should be between the ages of 18-85.

Exclusion criteria

Exclusion Criteria:

  • Patients unable to provide inform consent.
  • Prisoners and institutionalized individuals.
  • PSC with orthotopic liver transplantation
  • History of Roux En Y procedure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Primary Sclerosing Cholangitis (PSC)

    Subjects diagnosed with Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).

  • Control (non-PSC)

    Subjects without a diagnosis of Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).

06

What researchers measure

Primary outcomes

  1. Number of participants in study.

    Number of participants in study.

    Time frame: 20 years

Secondary outcomes

  1. Number of samples (per type)

    Number of samples collected (bile liquid, biliary cells)

    Time frame: 20 years

  2. Number of clinical phenotypes and/or observations.

    Number of clinical phenotypes and/or endpoints observed (i.e. disease progression, liver ca development, organoids.)

    Time frame: 20 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for Jan 2035, 165 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2021
First posted
Feb 15, 2021
StartActual
Mar 8, 2021
Primary completionEst.
Jan 1, 2035
CompletionEst.
Jan 1, 2035
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04753996
Lead sponsor
Mayo Clinic
Responsible party
Konstantinos N. Lazaridis, M.D. (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Feb 15, 2021
Start date
Mar 8, 2021
Primary completion
Jan 1, 2035 (estimated)
Completion
Jan 1, 2035 (estimated)
Last update
Feb 17, 2026

Study contacts

Erik Schlicht, CCRP
Contact
schlicht.erik@mayo.edu
(507) 284-4212
Jackie Bianchi
Contact
bianchi.jackie@mayo.edu
(507) 266-0346
Konstantinos Lazaridis, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion